All News

Article

Does Evusheld shield people living with rheumatic diseases?

Md Yuzaiful Md Yusof, MRCP(UK), PhD

While COVID vaccination and subsequent booster remain the cornerstone, pre-exposure prophylaxis such as Evusheld (tixagevimab and cilgavimab) has been approved by FDA in December 2021 and EMA in March 2022 for people immunocompromised either due to a medical condition or receiving treatment with immunosuppressants and may not mount an adequate immune response to COVID vaccination. How does this therapy fare in RMD patients?

Patricia Harkins Tweet
DrTrishHarkins
Congenital ❤️ Block in Ro/La pregnancies Abst#0957 👉1st echo @ mean 20wk 👉CHB 3/47- all on 1st echo 👉 1 reversed 3rd ➡️ 1st AVB post dexamethasone 🔥Key messages🔥 🤰serial echo should start @ 16-18wk gestation 👶 early detection ⬆️ outcomes #ACR22 @RheumNow
Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
#ACR22 Plenary II Abstr#1114 Access to therapy/Cost need to be improved since high copays (=> 10USD per month) affects adherence to treatment (HCQ, AZA, MMF but not MTX) in #lupus @RheumNow https://t.co/WnwIhpqDxL
David Liew Tweet
drdavidliew
"If I had one test in a difficult case of suspected PMR, it would be PET/CT" - @LCalabreseDO #ACR22 @RheumNow (credit: as heard by @drceowen) https://t.co/w88peUd4j1
Patricia Harkins Tweet
DrTrishHarkins
Mx aging rheumatic dx pt 🌟5M approach🌟 🧠Mind (mood/cog) 💊 Medication (polypharm) 🏃 Mobility 👉Multicomplexity (biopsychsoc) 💪🏻 Matters (aligning 2 specific goals) 💥Interdisciplinary💥 #GeriRheum #ACR22 @RheumNow @B_Buehring_MD @UnaMakris
Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
#ACR22 Plenary II. Abstr#1113 Promising news in #Sjogren. Phase 2 RCT showed oral BTK-i Remibrutinib improved ESSDAI score vs Placebo (delta -2.8) & salivary flow at Wks 24. ESSPRI unchanged. No major safety concern. Look forward to Phase 3 results soon @RheumNow #ACRBest https://t.co/z0oy9FvheY
Mike Putman Tweet
EBRheum
Sjogren's in a Plenary! Remibrutinib (BTKi) in SjS Improved ESSDAI at wk 24, but NONE on ESSPRI (more patient-centric ie fatigue, dryness, joint pain) Definitely helps w/lab abnormalities, but worried benefit for outcomes that matter may be limited #ACR22 @RheumNow abstr#1113 https://t.co/GutY8KndbR
Fabio Torres Tweet
FabioTorressav
@EBRheum @RheumNow Its more than that…tubulointerstitial kidney disease, lymph nodes, salivary gland, and hepatobiliary tract disease don’t show findings of vasculitis. Certain HLA haplotypes more linked with autoimmune diseases are present. #ACR @RheumNow
CreakyJoints.org Tweet
CreakyJoints
Dr. Jack Cush discusses uptake of #telemedicine in 2020 and the relative decline of uptake since then: @RheumNow -- What's your take on continuing to use #telehealth for rheum visits? #ACR22 https://t.co/OB5Wnnq6Fh
sheila Tweet
RHEUMarampa
Dr. Megan Clowse gives 2 major tips on how rheumatologists can help avoid catastrophic pregnancies: ✳️Routinely ask open-ended Qs to promote HONEST dialogue about repro health ✳️Provide ACCURATE info & guidance using discussion guides and handouts #ACR22 @RheumNow @rheumarhyme https://t.co/qXwKMdJmR8
Akhil Sood MD Tweet
AkhilSoodMD
Advancing Telemedicine in Rheumatology 'We all became Zoomatologists (Zheum-atologists?) since COVID.' -Jack Cush @RheumNow @RheumNow #ACR22
Olga Petryna Tweet
DrPetryna
#abs0948 #acr22 @rheumnow perception on fertility&ART in pts w/rheum Dx: 60% believe their Dx affects fertility/25% believe meds do: most cited MTX, steroids, TNFi, HCQ, NSAIDs. 92% heard of ART but unsure if safe or successful w/their Dx. Hx of infertility 29%/only 52% go w/ART https://t.co/lmaM773gP5
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×